The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the possibility for game-changing treatments and substantial returns is certain, the linked risks are also considerab